scholarly journals Formulation and evaluation of dexlansoprazole extended-release tablet

2021 ◽  
Vol 17 (3) ◽  
pp. 191-197
Author(s):  
Shubham Santosh Sharma ◽  
Pooja Ganesh Bhutada

Dexlansoprazole (DSP) is a proton pump inhibitor, it used to treat GERD and ulcer colitis. DSP works by decreasing the volume of acid in the stomach. DSP is an acid-labile medication that may be destroyed in the stomach's acidic pH. A coating technique was used to postpone drug release in the stomach, which can extend pharmacological activity. Shellac can be used to develop the sustain release tablet of dexlansoprazole as retardation of the drug (dexlansoprazole) was observed in the acidic pH of the stomach, and hence a sustain coated dexlansoprazole tablet was prepared and evaluated. The coating's primary function is to allow for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits faster degradation in the acidic pH of the stomach, therefore increasing pharmacological action. DSP coating with different polymers inhibits fast degradation in the stomach's acidic pH, enhancing pharmacological action. The major function of the coating is to enable for the delayed, immediate, and prolonged delayed release of DSP. DSP coating with different polymers inhibits fast breakdown in the stomach's acidic pH, enhancing pharmacological action.

2015 ◽  
Vol 35 (5) ◽  
pp. 291-297 ◽  
Author(s):  
Mona Darwish ◽  
Ronghua Yang ◽  
William Tracewell ◽  
Philmore Robertson ◽  
Mary Bond

Pain Medicine ◽  
2017 ◽  
Vol 19 (8) ◽  
pp. 1597-1612
Author(s):  
Mary Bond ◽  
Kerri A Schoedel ◽  
Laura Rabinovich-Guilatt ◽  
Maciej Gasior ◽  
William Tracewell ◽  
...  

2017 ◽  
Vol 34 (6) ◽  
pp. 1187-1192 ◽  
Author(s):  
Rajendar K. Mittapalli ◽  
Silpa Nuthalapati ◽  
Alyssa E. Delke DeBord ◽  
Hao Xiong

RSC Advances ◽  
2016 ◽  
Vol 6 (41) ◽  
pp. 34110-34119 ◽  
Author(s):  
Srinivasulu Aitipamula ◽  
Annie B. H. Wong ◽  
Pui Shan Chow ◽  
Reginald B. H. Tan

Novel solid forms of an anti-inflammatory drug, oxaprozin, were identified. A drug–drug salt of oxaprozin with salbutamol was proved promising for development of extended release tablet formulations of salbutamol.


Sign in / Sign up

Export Citation Format

Share Document